2020
Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States
Zeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaDecitabine-treated patientsTransfusion independenceRed blood cell transfusion independenceLarge population-based studyOlder AML patientsRBC transfusion independenceEnd Results-MedicarePopulation-based studyStandard of careAgent azacitidineMedian survivalOlder patientsIntensive therapyAML patientsClinical outcomesClinical benefitMyeloid leukemiaMortality riskPatientsAzacitidineDecitabineOlder adultsOne-thirdMeaningful differences
2015
Phase I/IIa trial of volasertib combined with decitabine in patients with acute myeloid leukemia (AML) ineligible for intensive therapy
Cortes J, Podoltsev N, Rajeswari S, Guo Z, Taube T, Uy G. Phase I/IIa trial of volasertib combined with decitabine in patients with acute myeloid leukemia (AML) ineligible for intensive therapy. Clinical Lymphoma Myeloma & Leukemia 2015, 15: s193. DOI: 10.1016/j.clml.2015.04.043.Peer-Reviewed Original Research